
USA - NASDAQ:CGIX -
The current stock price of CGIX is 4.61 null. In the past month the price decreased by -21.73%. In the past year, price increased by 45.89%.
Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.
Cancer Genetics Inc
201 ROUTE 17 NORTH 2ND FLOOR
RUTHERFORD NJ 07070
CEO: John A. Roberts
Phone: 201-528-9200
Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.
The current stock price of CGIX is 4.61 null. The price decreased by -2.33% in the last trading session.
CGIX does not pay a dividend.
CGIX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
CGIX stock is listed on the Nasdaq exchange.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CGIX.
ChartMill assigns a technical rating of 4 / 10 to CGIX. When comparing the yearly performance of all stocks, CGIX is one of the better performing stocks in the market, outperforming 76.32% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CGIX. Both the profitability and financial health of CGIX have multiple concerns.
Over the last trailing twelve months CGIX reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS increased by 60.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -71.5% | ||
| ROA | -46.7% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |